Cantor Fitzgerald Issues Positive Forecast for ABEO Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a report issued on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($0.96) per share for the year, up from their previous forecast of ($1.17). The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share.

A number of other equities analysts have also recently issued reports on ABEO. Stifel Nicolaus dropped their price objective on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a report on Friday, May 16th. Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Oppenheimer initiated coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an "outperform" rating and a $16.00 target price for the company. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Finally, HC Wainwright lifted their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Abeona Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $18.50.

Abeona Therapeutics Trading Down 2.4%

ABEO traded down $0.16 during trading on Wednesday, reaching $6.42. The company had a trading volume of 957,198 shares, compared to its average volume of 619,860. The business has a 50 day simple moving average of $5.29 and a 200-day simple moving average of $5.55. The stock has a market cap of $328.43 million, a P/E ratio of -2.39 and a beta of 1.68. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.11.

Insider Transactions at Abeona Therapeutics

In other news, Director Mark Alvino sold 8,000 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $5.68, for a total transaction of $45,440.00. Following the transaction, the director now directly owns 92,435 shares of the company's stock, valued at approximately $525,030.80. This represents a 7.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Vishwas Seshadri sold 25,000 shares of the firm's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. The trade was a 1.81% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Abeona Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. lifted its position in shares of Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. Western Standard LLC boosted its stake in Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after buying an additional 386,321 shares during the period. Jane Street Group LLC grew its stake in shares of Abeona Therapeutics by 894.8% in the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after buying an additional 118,262 shares in the last quarter. 683 Capital Management LLC increased its stake in Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock worth $4,411,000 after buying an additional 116,845 shares during the period. Finally, Newtyn Management LLC boosted its stake in shares of Abeona Therapeutics by 26.3% in the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock valued at $2,285,000 after buying an additional 100,000 shares during the period. Hedge funds and other institutional investors own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.